Delavirdine (Rescriptor) is approved for the treatment of HIV-1 infection in adults and adolescents over age 16 as part of a combination therapy. Rash accompanied by pruritus is the most frequent adverse effect of this agent; however, it usually resolves within several weeks of treatment. Severe skin reactions are rare. Headache, nausea, vomiting, diarrhea, fatigue, and elevated hepatic enzymes also may be associated with delavirdine administration.
Drugs that decrease stomach acidity (e.g., antacids, H2 receptor blockers, and proton pump inhibitors) de crease the absorption of delavirdine. In vivo and in vitro studies have shown that delavirdine is metabolized by and inhibits CYP3A4. In vitro studies have shown that it also is metabolized by CYP2D6 and inhibits CYP2C9, CYP2D6, and CYP2C19. Delavirdine should not be used in combination with alprazolam, cisapride, ergot alkaloids, midazolam, or triazolam because of the potential for serious adverse reactions. Delavirdine increases serum concentrations of certain protease inhibitors and may reverse the resistance of zidovudine-resistant HIV.
Was this article helpful?
Are Headaches Taking Your Life Hostage and Preventing You From Living to Your Fullest Potential? Are you tired of being given the run around by doctors who tell you that your headaches or migraines are psychological or that they have no cause that can be treated? Are you sick of calling in sick because you woke up with a headache so bad that you can barely think or see straight?